Abstract 14849: Lifetime Benefit of Empagliflozin in Extending Survival Free From Insulin Initiation in Type 2 Diabetes and Cardiovascular Disease: An Actuarial Analysis of EMPA-REG OUTCOME

Muthiah Vaduganathan,Naveed Sattar,David H Fitchett,Anne Pernille Ofstad,Martina Brueckmann,Jyothis T George,Subodh Verma,Michaela Mattheus,Christoph Wanner,Silvio E Inzucchi,Bernard Zinman,Javed Butler

Circulation（2020）

引用 0|浏览1

暂无评分

摘要

Background: Many patients with type 2 diabetes (T2D) will, over time, require insulin therapy for glycemic control. Treatment-attendant adverse effects of insulin such as weight gain and hypoglycem...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要